



The Illinois Medical Bulletin



The Impact of Targeting HER2 with Trastuzumab in Breast Cancer: A Review of a Paradigm-Shifting Therapy

¹A.Buckley, ²A. Burke

^{1,2} University of Illinois College of Medicine

Corresponding Email : buckleymd9838737@gmail.com

Article History :

Received date : 2017/10/12
Revised date : 2017/11/28
Accepted date : 2017/12/09
Published date : 2018/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: A significant subset of breast cancers is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2), a feature historically associated with an aggressive clinical course and a poor prognosis. The development of trastuzumab, a monoclonal antibody specifically targeting the HER2 protein, represented a pivotal advance in targeted oncology.

Literature Review: A review of the pivotal clinical trial literature demonstrates the transformative efficacy of trastuzumab in HER2-positive breast cancer. A landmark phase III trial in the metastatic setting definitively showed that the addition of trastuzumab to standard first-line chemotherapy resulted in significant improvements in response rates, time to disease progression, and overall survival. The benefit of this targeted therapy was even more profound when applied in the adjuvant (early-stage) setting. Large, international randomized trials conclusively proved that one year of trastuzumab following chemotherapy dramatically reduced the risk of disease recurrence and death, offering a cure to many more women. This

research also identified a key on-target toxicity, cardiotoxicity, which led to the integration of cardiac safety monitoring into routine clinical practice.

Conclusion: The body of evidence unequivocally established HER2-directed therapy with trastuzumab as the standard of care for all stages of HER2-positive breast cancer. This research fundamentally altered the natural history of this aggressive disease subtype, transforming it into a highly treatable condition and serving as a prime example of a successful, biomarker-driven therapeutic strategy.

Keywords: Breast Cancer, HER2, Trastuzumab, Targeted Therapy, Metastatic, Adjuvant Therapy.

INTRODUCTION

Breast cancer is not a single entity but a heterogeneous group of diseases with distinct molecular characteristics, clinical behaviors, and prognoses. One of the most important molecular subtypes is defined by the amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) gene. HER2-positive breast cancer, which accounts for a substantial fraction of all cases, was long recognized as being particularly aggressive, with a higher likelihood of recurrence and a shorter overall survival compared to HER2-negative tumors.

The identification of HER2 as a key oncogenic driver of these tumors provided a clear and rational therapeutic target. This led to the development of trastuzumab, a humanized monoclonal antibody designed to bind to the extracellular domain of the HER2 protein and inhibit its function. The clinical development of trastuzumab represents a landmark achievement in oncology, transforming the outlook for patients with this aggressive disease. This literature review will synthesise the pivotal clinical trial evidence that established the profound efficacy of trastuzumab in both metastatic and early-stage HER2-positive breast cancer.

LITERATURE REVIEW

The validation of trastuzumab as a cornerstone of breast cancer therapy was a multi-step process, with definitive trials establishing its benefit first in the advanced setting and later, even more impactfully, in the curative-intent setting.

The scientific rationale for targeting HER2 was strong. Overexpression of the HER2 receptor leads to the formation of receptor dimers that are constitutively active, sending a constant stream of powerful signals into the cell that promote uncontrolled proliferation and survival. Trastuzumab was designed to interfere with this process by binding to the receptor, preventing its dimerization, and flagging the cancer cell for destruction by the host's immune system.

The definitive proof of its clinical benefit in the metastatic setting came from a large, randomized phase III trial. This study compared the outcomes of women with HER2-positive metastatic breast cancer who received standard first-line chemotherapy either alone or in combination with trastuzumab. The results were unprecedented for a targeted agent at the time. The addition of trastuzumab to chemotherapy led to a longer time to disease progression, a higher tumor response rate, and most importantly, a significant and clinically meaningful improvement in median overall survival (Slamon et al., 2001). This trial firmly established the trastuzumab-chemotherapy combination as the new standard of care for the first-line treatment of this disease. The efficacy of trastuzumab as a single agent in pre-treated patients was also established (Vogel et al., 2002).

Building on this success, the next logical step was to investigate whether trastuzumab could prevent recurrence and improve cure rates in women with early-stage, non-metastatic HER2-positive breast cancer. Several massive, international, randomized adjuvant trials were launched to answer this question. The results, reported in a series of landmark publications, were even more dramatic than in the metastatic setting. The joint analysis of two major North American trials, NSABP B-31 and NCCTG N9831, and the results of the European-based HERA trial, were strikingly consistent. They all demonstrated that the addition of one year of trastuzumab to standard adjuvant chemotherapy cut the risk of disease recurrence by approximately half and also significantly reduced the risk of death (Romond et al., 2005; Piccart-Gebhart et al., 2005). These remarkable findings represented one of the most significant advances in the history of breast cancer treatment.

A crucial part of the trastuzumab story was the identification of a specific, on-target toxicity. The clinical trials revealed a small but significant risk of cardiotoxicity, manifesting as an asymptomatic decline in left ventricular ejection fraction or, less commonly, symptomatic congestive heart failure. The risk was found to be highest when trastuzumab was administered concurrently with anthracycline-based chemotherapy. This discovery did not diminish the

drug's profound overall benefit, but it did lead to the universal implementation of rigorous cardiac monitoring protocols for all patients receiving this life-saving therapy (Seidman et al., 2008).

CONCLUSION

The pivotal literature on the use of trastuzumab in HER2-positive breast cancer chronicles a true revolution in oncology. This body of evidence documents the successful translation of a key molecular insight into a highly effective, life-saving therapy. The research definitively proved that targeting the HER2 receptor with trastuzumab provides a substantial survival benefit for patients with metastatic disease and, even more importantly, dramatically improves the chances of a cure for patients with early-stage disease.

This work fundamentally altered the natural history of what was once one of the most feared forms of breast cancer, converting it into one of the most treatable. The story of trastuzumab established a new paradigm for cancer treatment, providing a quintessential example of how a biomarker-driven, personalized approach can lead to profound improvements in patient outcomes.

REFERENCES

Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C.H., Steger, G., Eirmann, W., Suter, T.M., "Herceptin Adjuvant (HERA) Trial Study Team". (2005) 'Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer', *New England Journal of Medicine*, 353(16), pp. 1659-1672.

Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E., Jr., Davidson, N.E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P.A., Swain, S.M., Pisansky, T.M., Fehrenbacher, L., Kutteh, L.A., Vogel, V.G., Visscher, D.W., Yothers, G., Jenkins, R.B., Brown, A.M., Dakhil, S.R., Mamounas, E.P., Lingle, W.L., Klein, P.M., Ingle, J.N. and Wolmark, N. (2005) 'Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer', *New England Journal of Medicine*, 353(16), pp. 1673-1684.

Seidman, A.D., Hudis, C.A. and Pierri, M.K. (2008) 'Cardiac dysfunction in the trastuzumab clinical trials experience', *Journal of Clinical Oncology*, 26(8), pp. 1219-1226.

Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J. and Norton, L. (2001) 'Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2', *New England Journal of Medicine*, 344(11), pp. 783-792.

Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., Shak, S. and Stewart, S.J. (2002) 'Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer', *Journal of Clinical Oncology*, 20(3), pp. 719-726.